Twist Bioscience (NASDAQ:TWST) Stock Gets Price Target Reduction from TD Cowen

Twist Bioscience (NASDAQ:TWST – Free Report) had its price objective decreased by TD Cowen from $190.00 to $137.00 in a research note released on Friday, MarketBeat.com reports. TD Cowen currently has a buy rating on the stock.

Several other analysts also recently issued reports on the company. UBS Group assumed coverage on Twist Bioscience in a research note on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, September 21st. Robert W. Baird reduced their target price on Twist Bioscience from $187.00 to $135.00 and set an “outperform” rating for the company in a report on Friday. Piper Sandler upped their target price on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Finally, Barclays upped their target price on Twist Bioscience from $112.00 to $215.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Seven analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Twist Bioscience currently has a consensus rating of “Hold” and an average target price of $141.00.

View Our Latest Research Report on TWST

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST opened at $111.60 on Friday. The stock has a market capitalization of $7.00 billion, a PE ratio of -53.40 and a beta of 2.25. Twist Bioscience has a 1 year low of $23.30 and a 1 year high of $219.71. The firm has a fifty day moving average price of $150.23 and a 200 day moving average price of $93.07. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.07. Twist Bioscience had a negative net margin of 28.34% and a negative return on equity of 27.53%. The firm had revenue of $126.64 million for the quarter, compared to the consensus estimate of $123.55 million. Twist Bioscience’s revenue was up 26.7% compared to the same quarter last year. Analysts expect that Twist Bioscience will post -1.52 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Paula Green sold 10,088 shares of the business’s stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $1,905,421.44. Following the completion of the transaction, the senior vice president owned 106,632 shares of the company’s stock, valued at approximately $20,140,652.16. The trade was a 8.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Dennis Cho sold 9,514 shares of the stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $1,797,004.32. Following the sale, the insider owned 63,789 shares of the company’s stock, valued at approximately $12,048,466.32. The trade was a 12.98% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 495,279 shares of company stock valued at $80,489,387. Company insiders own 3.08% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Hedge funds have recently modified their holdings of the business. Entropy Technologies LP grew its stake in shares of Twist Bioscience by 69.8% in the third quarter. Entropy Technologies LP now owns 19,357 shares of the company’s stock worth $3,741,000 after acquiring an additional 7,955 shares during the last quarter. Pathstone Holdings LLC acquired a new position in Twist Bioscience during the 3rd quarter valued at $474,000. Empowered Funds LLC raised its stake in Twist Bioscience by 182.6% during the 3rd quarter. Empowered Funds LLC now owns 5,881 shares of the company’s stock valued at $1,136,000 after purchasing an additional 3,800 shares during the last quarter. Steward Partners Investment Advisory LLC raised its stake in Twist Bioscience by 99.0% during the 3rd quarter. Steward Partners Investment Advisory LLC now owns 203 shares of the company’s stock valued at $39,000 after purchasing an additional 101 shares during the last quarter. Finally, New World Advisors LLC bought a new stake in Twist Bioscience in the 3rd quarter valued at $267,000.

More Twist Bioscience News

Investors following TWST have been watching these news items:

About Twist Bioscience

(Get Free Report)

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.

See Also

Analyst Recommendations for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.